Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus ADC vaccine in MSS metastatic colorectal cancer
NCT03152565Phase 2Completed
- Sponsor
- GEMCAD
- Start
- Mar 2018
- Primary completion
- Jun 2019
- Modality
- Prophylactic Vaccines, Immune Checkpoint Inhibitors, Whole Cell Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab and autologous dendritic cell vaccine in colorectal cancer (CRC), sponsored by GEMCAD. Primary endpoints: Dose of Avelumab in combination with Autologous Dendritic Cells at 18 months and Progression Free Survival at 6 months. Started Mar 2018; status: completed.
02
Drugs
avelumabautologous dendritic cell vaccine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03152565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03152565.